大剂量甲孕酮治疗复发转移乳癌

CLINICAL TRIAL OF HIGH DOSE MEDROXYPROGESTERONE ACETATE IN ADVANCED BREAST CANCER

６２例复发转移乳癌患者接受口服大剂量甲孕酮治疗，５００ｍｇ／次，２～３次／天，３０天为一疗程。近期客观疗效：ＣＲ１．６％（１／６２），ＰＲ５３．２％（３３／３２），ＳＤ１７．７％（１１／６２），ＰＤ２７．４％（１７／６２）；骨转移、肺转移、胸壁软组织转移效果较好，胸腔积液、肝转移也有一定疗效。结果显示疗效与年龄有关，而与疗前一般状况积分（ＫＰＳ）、月经状况、既往激素治疗、术后无病生存期、复发转移部位数目、甲孕酮剂量无关；ＥＲ阳性患者有效率较ＥＲ阴性高，但统计学处理差异无显著性意义。口服大剂量甲孕酮治疗毒性反应较轻，主要是体重增加、出汗过多。

Abstract Sixty two evaluable patients with advanced breast cancer were treated with medroxyprogesterone acetate (Farlutal. Erba) 500mg orally twice or three times a day.After thirtydays, one patient had a complete response (1.6%) ,33 patients had partial response (53.2%). 11hadstable disease(17.7%) ,and 17 had progressive disease (27.4%). The response rates of bone , lungand chest wall metastasis were higher. And the older patients showed a better response than theyounger. The response did not show signifincant correlation with KPS,menopausal status ,diseas free intervals after operation ,numbers of metastases and the dose of medroxyprogesterone acetate.The response rate in ER positive patients was higher than the ER negative,but the difference was notstatisticaly different.The side effects of high dose medroxyprogesterone acetate were well toleratedand the most common ones were weight gain and excessive perspiraion.